Startups
ARTAN is a biotechnology company developing a novel approach to address genetic and age-related diseases caused by nonsense mutations. These mutations lead to premature protein translation stops, resulting in incomplete and nonfunctional proteins. Our pipeline involves an engineered suppressor system that specifically recognizes these codons and restores normal protein translation.
Mentions in press and media 4
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jul 2, 2026 | Artan Bio Closes $1M Seed Funding Round | Artan Bio, a St. Petersburg, Florida-based developer of engineered transfer RNA (tRNA) therapies for mutation-driven aging biology, closed a $1m seed funding round. The round was led by company co-founder Michael Torres, Ph.D., following hi... |
| Jan 23, 2025 | How Molecule is accelerating medical research through tokenised IP and decentralised biotech funding | Academic research is challenging. Obtaining grants and financial support for research projects is highly competitive and time-consuming. Researchers typically juggle multiple projects, including teaching, and they also have to deal with rea... |
| Artan Biotechnologies | “ARTAN is a biotechnology company developing a novel approach to address genetic and age-related diseases caused by nonsense mutations. These mutations lead to premature protein translation stops, resulting in incomplete and nonfunctional p... |
Reviews 0
FAQ about ARTAN BIO
What has the press written about ARTAN BIO?
Parsers VC has collected 4 articles mentioning ARTAN BIO, among them “Artan Bio Closes $1M Seed Funding Round” (Jul 2, 2026) and “How Molecule is accelerating medical research through tokenised IP and decentralised biotech funding” (Jan 23, 2025).
Is ARTAN BIO still active?
ARTAN BIO is probably closed: its latest activity on Parsers VC dates from Jul 3, 2026.